
FDA Approves Additional Dose of COVID-19 Vaccine for Immunocompromised Patients
The US Food and Drug Administration (FDA) announced it has authorized a third dose of either the Pfizer/BioNTech or Moderna mRNA COVID-19 vaccines for patients with compromised immune systems, such as patients with rheumatic disease.
This article was originally
Patients with rheumatic disease are more likely to be on immunosuppressive medications and are more susceptible to infection. The booster shots ensure an extra precautionary measure for this patient population.
The US Food and Drug Administration (FDA) announced Thursday it has authorized a third dose of either the Pfizer/BioNTech or Moderna mRNA COVID-19 vaccines for patients with compromised immune systems.
In a
“The FDA expanded the emergency use authorization (EUA) for both the Pfizer/BioNTech and Moderna vaccines. That decision will then be evaluated by the CDC’s
The ruling was primarily made to benefit organ transplant patients but others with compromised immune systems, such as those battling cancer and HIV, would also be eligible for booster shots. About 2.7% of adults in the United States are immunocompromised,
The FDA encourages such patients to explore treatment options with their health care providers should they contract COVID-19 or be exposed to someone with COVID-19.



